CGTX Cognition Therapeutics, Inc.

NASDAQ
$0.94

Cognition Therapeutics, Inc. (CGTX) is expected to report earnings on November 3, 2026, after the market close. The consensus earnings estimate is a loss of $0.07 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -14.9% since its last earnings release on August 6, 2026.

Cognition Therapeutics, Inc. Beat Consensus Estimates
Thursday, August 6, 2026 · 4:15 PM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 3
Tuesday · 4:15 PM ET
Earnings Whisper
-
vs ($0.07)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $1.02

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Cognition Therapeutics, Inc.

Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system, or CNS, and retina.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.